Latest Strategic Initiatives News

Mesoblast Limited is set to release its half-year financial results and operational update, spotlighting its FDA-approved cell therapy and expanding international partnerships.

Contact Energy has issued over 51 million new shares at NZD 8.75 each, representing a 5.17% increase in its ordinary shares, aiming to strengthen its shareholder base through a carefully structured placement.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

Boom Logistics has reported a record half-year revenue of $142.2 million for 1H FY26, alongside upgraded earnings guidance and an expanded share buy-back program, signalling strong operational momentum despite sector challenges.

Zip Co Limited has announced a $50 million on-market share buy-back program starting in March 2026, signalling confidence in its financial position and commitment to capital management.

Guzman y Gomez has reported a robust first half of FY26, delivering strong revenue and profit growth alongside significant restaurant network expansion in Australia and the US.

EQT Holdings Limited has reported a strong half-year performance with an 11.8% revenue increase and a 67% surge in profit after tax, while announcing a fully franked interim dividend of 56 cents per share despite suspending its dividend reinvestment plan.

Medical Developments International (MVP) reported an 8% revenue increase driven by strong Penthrox growth, despite a slight EBIT loss impacted by foreign exchange. The company advances pediatric approvals and targets further volume gains.

Articore Group Limited reports a significant turnaround in 1HFY26 with improved profitability and margin expansion, prompting an upgrade to its FY26 EBIT guidance. The company’s strategic initiatives in marketing, supply chain, and technology are driving renewed momentum.

IPH Limited reported a solid half-year performance with revenue up 6.5% to $363.9 million and net profit rising 10.5% to $41.2 million, driven by strong gains in Canada and Asia despite a decline in Australia and New Zealand.

Insignia Financial Group reported a strong half-year with revenue up 7.8% and profit after tax surging 569%, despite a significant impairment on an associate investment and no dividends declared.

Cogstate Limited reported a solid 12% increase in revenue to $26.9 million for the half-year ended December 2025, driven by growth in its Clinical Trials segment and a 2% rise in net profit before tax. The company’s contracted future Clinical Trials revenue also grew 10%, signalling strong momentum ahead.